NEW YORK (GenomeWeb) — Nanosphere said today that it has been selected by HealthTrust to provide multi-target molecular diagnostic tests for nearly 1,400 acute care facilities that are part of the HealthTrust membership.
Under the agreement, HealthTrust's members will have access to purchase Nanosphere's portfolio of Verigene multiplex molecular diagnostics tests for infectious diseases, including assays for detecting infections of the bloodstream, respiratory tract, and gastrointestinal tract.
The agreement went into effect June 1, Northbrook, Ill.-based Nanosphere said.
The Verigene system uses Nanosphere's core proprietary gold nanoparticle chemistry to offer highly sensitive, specific, multiplexed and low-cost molecular diagnostic tests.
HealthTrust, legally known as HealthTrust Purchasing Group, provides cost management services to healthcare businesses. In addition to the approximately 1,400 acute care facilities, the Brentwood, Tenn.-based company serves 800 ambulatory surgery centers and members in more than 10,600 other locations, including physician practices, long-term care, and alternate care sites.